Showing 3361-3370 of 5646 results for "".
- Coburn Technologies Introduces New Spin Coater with Dual-Coating Technology, Velocity 2Dhttps://modernod.com/news/coburn-technologies-introduces-new-spin-coater-with-dual-coating-technology-velocity-2d/2476376/Coburn Technologies has introcued the Velocity 2D, the next generation of the Velocity Automated Spin Coater, now designed with dual-coating technology. Derived from the existing platform of the ground-breaking Velocity automated lens coater, the Velocity 2D now offers labs the ability to
- Roche/Genentech Study Shows First-Time Proof That AI Can Detect Severity of DMEhttps://modernod.com/news/roche-genentech-study-shows-first-time-proof-that-ai-can-detect-severity-of-dme/2476347/A new study published in the journal
- Pharmaceutical Executives Field Questions at US Senate Hearing Over Drug Pricinghttps://modernod.com/news/pharmaceutical-executives-field-questions-at-us-senate-hearing-over-drug-pricing/2476258/CEOs and senior executives from AbbVie, AstraZeneca, Bristol-Myers Squibb, Merck & Co., Pfizer, Sanofi, and Johnson & Johnson appeared before the US Senate Finance Committee on Tuesday to testify about the high cost of drugs in the country. The executives, who continued to blame pharmacy
- LumiThera Receives Notice of Award for $2.5 Million National Eye Institute Grant to Support U.S. Multicenter Clinical Trial for Treating Dry AMDhttps://modernod.com/news/lumithera-receives-notice-of-award-for-2-5-million-national-eye-institute-grant-to-support-u-s-multicenter-clinical-trial-for-treating-dry-amd/2476262/LumiThera announced that it is a recipient of a small business innovative research (SBIR) phase 2 grant from the National Institute of Health (NIH) and the division of the National Eye Institute (NEI). The grant supports a prospective, randomized, multicenter human clinical trial in U.S. subjects
- Roche Acquires Spark Therapeutics in $4.8 Billion Dealhttps://modernod.com/news/roche-acquires-spark-therapeutics-in-4-3-billion-deal/2476268/Swiss pharma giant Roche acquired and Philadelphia-based gene therapy company Spark Therapeutics in an all cash transaction worth $4.8 billion, or $114.50 per share. The merger has been unanimously approved by the boards of Spark Therap
- TopiVert Announces Publication of Data from its Positive Phase 2 Study of TOP1630 in Dry Eye Diseasehttps://modernod.com/news/topivert-announces-publication-of-data-from-its-positive-phase-2-study-of-top1630-in-dry-eye-disease/2476303/TopiVert Pharma, a clinical-stage biotechnology company developing non-systemic kinase inhibitors (NSKIs) as novel, locally-acting medicines for the treatment of chronic inflammatory ocular diseases, announces the publication of the
- One-Year Results from Phase 3 Eylea Trial in Diabetic Retinopathy Presentedhttps://modernod.com/news/one-year-results-from-positive-phase-3-eylea-trial-in-diabetic-retinopathy-presented-at-angiogenesis-symposium/2476306/Regeneron Pharmaceuticals announced that positive detailed 1-year results from the phase 3 PANORAMA trial evaluating Eylea (aflibercept) injection in patients with moderately severe to severe nonproliferative diabetic retinopathy (NPDR)
- CEI Vision Partners Adds Virginia Eye Consultants as Fifth Partnerhttps://modernod.com/news/cei-vision-partners-adds-virginia-eye-consultants-as-fifth-partner/2476310/CEI Vision Partners (CVP), a portfolio company of Revelstoke Capital Partners LLC , a Denver-based private equity firm, has completed a partnership with Virginia Eye Consultants (VEC) , a premier multi-specialty ophthalmology group comprised of 17 providers that service the Norfolk, Virginia Beac
- Galimedix Therapeutics Presents Data for Investigational Eyedrops Containing GAL-101https://modernod.com/news/galimedix-therapeutics-presents-data-for-investigational-eyedrops-containing-gal-101/2476320/Galimedix Therapeutics, which is developing new solutions for ophthalmic and neurodegenerative diseases, presented an overview of data disclosed to date on its novel, first-in-class, investigational compound GAL-101, which in animal models caused sustained prevention of misfolded amyloid beta mol
- Bausch Health Reduces Debt By Additional $100 Millionhttps://modernod.com/news/bausch-health-reduces-debt-by-additional-100-million/2476341/Bausch Health Companies, the parent company of Bausch + Lomb, announced it has paid down an additional $100 million of its senior secured term loans using cash generated from operations. “As Bausch Health pivots to offense in 2019, we continue to remain